Market closedNon-fractional
IO Biotech/IOBT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About IO Biotech
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Ticker
IOBT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Copenhagen, Denmark
Employees
70
Website
www.iobiotech.com
IO Biotech Metrics
BasicAdvanced
$88M
Market cap
-
P/E ratio
-$1.68
EPS
0.47
Beta
-
Dividend rate
Price and volume
Market cap
$88M
Beta
0.47
Financial strength
Current ratio
11.24
Quick ratio
10.766
Long term debt to equity
1.429
Total debt to equity
2.006
Management effectiveness
Return on assets (TTM)
-44.21%
Return on equity (TTM)
-73.84%
Valuation
Price to book
0.76
Price to tangible book (TTM)
0.76
Price to free cash flow (TTM)
-0.861
Growth
Earnings per share change (TTM)
-32.27%
3-year earnings per share growth (CAGR)
-73.88%
What the Analysts think about IO Biotech
Analyst Ratings
Majority rating from 6 analysts.
IO Biotech Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$19M
-25.67%
Profit margin
0.00%
NaN%
IO Biotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.74
-$0.43
-$0.40
-$0.30
-
Expected
-$0.66
-$0.44
-$0.39
-$0.36
-$0.35
Surprise
12.12%
-3.15%
3.09%
-16.67%
-
IO Biotech News
AllArticlesVideos
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
GlobeNewsWire·1 day ago
IO Biotech to Present at Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IO Biotech stock?
IO Biotech (IOBT) has a market cap of $88M as of July 27, 2024.
What is the P/E ratio for IO Biotech stock?
The price to earnings (P/E) ratio for IO Biotech (IOBT) stock is 0 as of July 27, 2024.
Does IO Biotech stock pay dividends?
No, IO Biotech (IOBT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next IO Biotech dividend payment date?
IO Biotech (IOBT) stock does not pay dividends to its shareholders.
What is the beta indicator for IO Biotech?
IO Biotech (IOBT) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell IO Biotech stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.